Urinary Incontinence

Nephrology·MeSH: Urinary Incontinence

Prevalence

10000.0 / 100K

Incidence

800.0 / 100K/yr

9 drugs in development·3 companies·8 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
toviaz	PFIZER INC (PFE)

Phase 1(1)

Drug	Company
Orforglipron	ELI LILLY & Co (LLY)

Phase 4(7)

Drug	Company
1% lidocaine with sodium bicarbonate	Revance Therapeutics, Inc. (RVNC)
Beta3-Agonists, Adrenergic [Mirabegron/Vibegron]	Revance Therapeutics, Inc. (RVNC)
Botox® injection	Revance Therapeutics, Inc. (RVNC)
onabotulinumtoxin A	Revance Therapeutics, Inc. (RVNC)
OnabotulinumtoxinA	Revance Therapeutics, Inc. (RVNC)
OnabotulinumtoxinA 100 UNT [Botox]	Revance Therapeutics, Inc. (RVNC)
Phenazopyridine	Revance Therapeutics, Inc. (RVNC)

BioSniper tracks 9 drugs in development for Urinary Incontinence across 3 companies.

There are 8 clinical trials targeting Urinary Incontinence tracked by BioSniper.

The estimated prevalence of Urinary Incontinence is approximately 10000.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.